The concept of PRMT5 targeting via competitive inhibition of the substrate has been observed to lead to the clinical development of EPZ015666 and a modified version of EPZ015866 as a treatment for MCL [25,26]. The gene discussed is PRMT5; the disease is mantle cell lymphoma.